|By PR Newswire||
|March 14, 2014 08:00 AM EDT||
NEW YORK, March 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Incorporated (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), Cigna Corporation (NYSE: CI), and OXiGENE, Inc. (NASDAQ: OXGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
UnitedHealth Group Incorporated Analyst Notes
On March 11, 2014, UnitedHealth Group Incorporated (UnitedHealth Group) announced that its UnitedHealthcare business has provided a $1.0 million grant for the Connecticut Children's Medical Center's Office for Community Child Health (OCCH) to help improve care delivery and address critical public health issues for children. UnitedHealthcare expects the grant to help create a Maintenance of Certification program to train primary care paediatricians in managing diseases. "We are proud to partner with UnitedHealthcare to support pediatricians' lifelong learning and professional development," said Paul Dworkin, M.D., Director of OCCH. "Together, we will enhance the quality and capacity of pediatric care to address an array of critical health issues, and help promote the healthy development of children in Connecticut and nationwide." The full analyst notes on UnitedHealth Group Incorporated are available to download free of charge at:
Bristol-Myers Squibb Company Analyst Notes
On March 5, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz with ritonavir. According to the Company, the study, which was presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI), highlights the unique mechanism of action of the investigational prodrug BMS-663068, which when converted into BMS-626529, a novel attachment inhibitor, prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell. "These study results are encouraging and support further development of BMS-663068 as we continue to look for ways to treat people living with HIV, especially those who have exhausted available therapies and are difficult to treat," said Douglas Manion, M.D., Senior Vice President of Development, Virology at Bristol-Myers Squibb. The full analyst notes on Bristol-Myers Squibb Company are available to download free of charge at:
AbbVie Inc. Analyst Notes
On March 3, 2014, AbbVie Inc. (AbbVie) presented the first detailed results of its pivotal phase III study, PEARL-III, at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). The Company informed that PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with AbbVie's investigational therapy with or without ribavirin (RBV) in non-cirrhotic, adult patients with chronic genotype 1b (GT1b) hepatitis C virus (HCV) infection who were new to treatment. The results revealed that PEARL-III was able to meet its primary and secondary endpoints. "We are excited about the strong PEARL-III results which demonstrate the AbbVie regimen achieved high SVR rates with no discontinuations due to adverse events in patients new to treatment with genotype 1b infection," said Scott Brun, M.D., Vice President of Pharmaceutical Development at AbbVie. "Additionally, with these data, we continue to be on track to begin major regulatory submissions in the second quarter of 2014. AbbVie will continue to disclose additional detailed phase III study results at future scientific congresses and in publications." The full analyst notes on AbbVie Inc. are available to download free of charge at:
Cigna Corporation Analyst Notes
On March 3, 2014, Cigna Corporation (Cigna) and the Baton Rouge Clinic announced that they have launched a collaborative accountable care initiative, which aims to improve patient access to health care, enhance care coordination, and achieve the "triple aim" of improved health, affordability, and patient experience. Under the program, the Baton Rouge Clinic will monitor and coordinate all aspects of an individual's medical care. "We look forward to expanding our collaborative accountable care program across Louisiana with the addition of the Baton Rouge Clinic," said Mark Netoskie, M.D., Senior Medical Director for Louisiana at Cigna. "Our goal is to create a health care system focused on providing quality care for the patient, which will ultimately lead to a healthier population and lower medical costs." The full analyst notes on Cigna Corporation are available to download free of charge at:
OXiGENE, Inc. Analyst Notes
On March 11, 2014, OXiGENE, Inc. (OXiGENE) announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. OXiGENE stated that the study has met its primary endpoint of a statistically significant increase in progression-free survival for the combination, as compared to bevacizumab alone. "ZYBRESTAT is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need," said Peter Langecker, M.D., Ph.D., CEO of OXiGENE. The full analyst notes on OXiGENE, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
Oct. 7, 2015 05:00 AM EDT Reads: 956
Oct. 7, 2015 05:00 AM EDT Reads: 807
Oct. 7, 2015 04:00 AM EDT Reads: 450
Oct. 7, 2015 03:30 AM EDT Reads: 455
Oct. 7, 2015 03:00 AM EDT Reads: 691
Oct. 7, 2015 03:00 AM EDT Reads: 400
Oct. 7, 2015 03:00 AM EDT Reads: 367
Oct. 7, 2015 02:45 AM EDT
Oct. 7, 2015 02:00 AM EDT Reads: 508
Oct. 7, 2015 02:00 AM EDT Reads: 251
Oct. 7, 2015 02:00 AM EDT Reads: 586
Oct. 7, 2015 01:15 AM EDT Reads: 506
Oct. 7, 2015 12:45 AM EDT Reads: 130
Oct. 7, 2015 12:00 AM EDT Reads: 504
Oct. 6, 2015 10:00 PM EDT Reads: 660